Efficacy of fetal stem cells in Duchenne muscular dystrophy therapy

Sych, Nataliia; Klunnik, Mariya; Ivankova, Olena; Matyaschuk, Irina; Demchuk, Mariya; Nоvytska, A. V.; Arkhipenko, Inna; Shalita, Iuliia; Siniscalco, Dario

doi:10.2147/jn.s57276

Cited by 6 publications

(4 citation statements)

References 36 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The clinical guidelines presented in this document apply more to mature/functionally differentiated cell therapy. To date, clinical trials of treatments based on those categories of cells have been carried out in over 40 countries with documented safety and functional neurological improvement for patients with CNS diseases and damage 74 – 114 .…”

Section: Introductionmentioning

confidence: 99%

Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017)

et al. 2018

Self Cite

View full text Add to dashboard Cite

Cell therapy has been shown to be a key clinical therapeutic option for central nervous system diseases or damage. Standardization of clinical cell therapy procedures is an important task for professional associations devoted to cell therapy. The Chinese Branch of the International Association of Neurorestoratology (IANR) completed the first set of guidelines governing the clinical application of neurorestoration in 2011. The IANR and the Chinese Association of Neurorestoratology (CANR) collaborated to propose the current version “Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017)”. The IANR council board members and CANR committee members approved this proposal on September 1, 2016, and recommend it to clinical practitioners of cellular therapy. These guidelines include items of cell type nomenclature, cell quality control, minimal suggested cell doses, patient-informed consent, indications for undergoing cell therapy, contraindications for undergoing cell therapy, documentation of procedure and therapy, safety evaluation, efficacy evaluation, policy of repeated treatments, do not charge patients for unproven therapies, basic principles of cell therapy, and publishing responsibility.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017)

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…Therefore, stem cells effect in false acupoints or placebos could result in the same mechanism of action, explaining the reduction in plasma CPK among treatments. The CPK decreasing is a good parameter to monitor the treatment [ 47 , 48 ].…”

Section: Resultsmentioning

confidence: 99%

Aquapuncture Using Stem Cell Therapy to Treat Mdx Mice

Esper

Pignatari

Rodrigues

et al. 2015

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Duchenne muscular dystrophy (DMD) occurs due to genetic mutations that lead to absence or decrease of dystrophin protein generating progressive muscle degeneration. Cell therapy using mesenchymal stem cell (MSC) has been described as a treatment to DMD. In this work, MSC derived from deciduous teeth, called stem cells from human exfoliated deciduous teeth (SHED), were injected in acupoint as an alternative therapy to minimize muscle degeneration in twenty-two mdx mice. The treatment occurred three times with intervals of 21 days, and animals were analyzed four times: seven days prior treatment (T-7); 10 days after first treatment (T10); 10 days after second treatment (T31); and 10 days after third treatment (T52). Animals were evaluated by wire test for estimate strength and blood was collected to perform a creatinine phosphokinase analysis. After euthanasia, cranial tibial muscles were collected and submitted to histological and immunohistochemistry analyses. Treated groups presented improvement of strength and reduced creatinine phosphokinase levels. Also, a slight dystrophin increase was observed in tibial cranial muscle when aquapuncture was associated SHED. All therapies have minimized muscle degeneration, but the association of aquapuncture with SHED appears to have better effect, reducing muscle damage, suggesting a therapeutic value.

show abstract

“…Moreover, stem cells could promote muscle regeneration through their properties of self-renewal and differentiation, as demonstrated in several pre-clinical models [23] . The rationale for the use of FSCs derived from liver and brain tissue, administered on different days, is based on our previous experience [24] . In Duchenne MD, FSCs could exert a beneficial effect based not only on their ability to differentiate into functional cells, but also through a trophic paracrine effect, as they can secrete diffusible growth factors.…”

Section: Discussionmentioning

confidence: 99%

Fetal Stem Cells are Effective in the Treatment of Grade I and II Respiratory Failure in Amyotrophic Lateral Sclerosis and Muscular Dystrophy

Sych¹,

Ivankova²,

Klunnyk³

et al. 2015

Translational Neuroscience and Clinics

Self Cite

View full text Add to dashboard Cite

Objectives: To study the effect of fetal stem cell (FSC) therapy on Grade Ⅰ and Ⅱ respiratory failure in patients with amyotrophic lateral sclerosis (ALS) and muscular dystrophy (MD).Methods: A comparative study was conducted on 41 patients with Grade Ⅰ or Ⅱ respiratory failure (RF) resulting from ALS or MD. The patients were divided into 4 groups according to the underlying disease and the degree of RF. Patients underwent combined treatment, including the experimental application of FSC therapy, and were examined before FSC treatment, and 6 months and 12 months after treatment.Results: FSC treatment improved both subjective and objective breathing parameters as early as 6 months post-treatment. A significant increase in the forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV 1 ) was reported by all patients with Grade Ⅰ RF linked to ALS and MD compared to baseline. Patient respiratory improvement was maintained over the next 6 months. Grade Ⅱ RF patients with MD reported a significant improvement in FVC 12 months after treatment.Conclusions: Evidence for respiratory improvement was observed as early as 6 months in all patients after combined treatment including FSC therapy, and this was maintained for a further 6 months after therapy. In MD patients with Grade Ⅱ RF, treatment resulted in a significant FVC and FEV 1 increase within 6 months and downgrading to Grade Ⅰ RF within a year after FSC treatment.

show abstract

Efficacy of fetal stem cells in Duchenne muscular dystrophy therapy

Cited by 6 publications

References 36 publications

Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017)

Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017)

Aquapuncture Using Stem Cell Therapy to Treat Mdx Mice

Fetal Stem Cells are Effective in the Treatment of Grade I and II Respiratory Failure in Amyotrophic Lateral Sclerosis and Muscular Dystrophy

Contact Info

Product

Resources

About